Vanguard Group Inc Aerovate Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,105,289 shares of AVTE stock, worth $3.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,105,289

Previous 672,275 64.41%

Holding current value

$3.05 Million

Previous $19.9 Million 90.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.41 - $30.75 $610,549 - $13.3 Million	433,014 Added 64.41%	1,105,289 $1.83 Million
Q1 2024 May 10, 2024	BUY	$17.68 - $29.57 $803,449 - $1.34 Million	45,444 Added 7.25%	672,275 $19.9 Million
Q4 2023 Feb 14, 2024	BUY	$9.58 - $24.25 $265,643 - $672,428	27,729 Added 4.63%	626,831 $14.2 Million
Q3 2023 Nov 14, 2023	BUY	$12.9 - $18.88 $974,401 - $1.43 Million	75,535 Added 14.43%	599,102 $8.13 Million
Q2 2023 Aug 14, 2023	BUY	$15.63 - $22.01 $160,285 - $225,712	10,255 Added 2.0%	523,567 $8.98 Million
Q1 2023 May 15, 2023	BUY	$19.17 - $27.7 $265,216 - $383,229	13,835 Added 2.77%	513,312 $10.4 Million
Q4 2022 Feb 10, 2023	BUY	$15.92 - $30.52 $529,260 - $1.01 Million	33,245 Added 7.13%	499,477 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $351,983 - $614,601	23,831 Added 5.39%	466,232 $7.73 Million
Q2 2022 Aug 12, 2022	SELL	$10.8 - $16.91 $407,257 - $637,659	-37,709 Reduced 7.85%	442,401 $6.92 Million
Q1 2022 May 13, 2022	BUY	$8.25 - $18.33 $97,308 - $216,202	11,795 Added 2.52%	480,110 $8.8 Million
Q4 2021 Feb 14, 2022	SELL	$9.14 - $21.54 $2.86 Million - $6.74 Million	-313,060 Reduced 40.07%	468,315 $5.52 Million
Q3 2021 Nov 12, 2021	BUY	$11.76 - $22.49 $9.19 Million - $17.6 Million	781,375 New	781,375 $16.4 Million

Others Institutions Holding AVTE

# of Institutions

Shares Held

27.7M

Call Options Held

185K

Put Options Held

115K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $67.5M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Aerovate Therapeutics, Inc. Transaction History